stockrowCoherus Oncology, Inc. (CHRS) vs TuHURA Biosciences, Inc. (HURA)
- Coherus Oncology, Inc. CHRS 0.54 −6.90%
- TuHURA Biosciences, Inc. HURA 1.45 −4.61%
Coherus Oncology, Inc. and TuHURA Biosciences, Inc. are both Biotechnology companies. Coherus Oncology, Inc. and TuHURA Biosciences, Inc. are of similar size ($96.9M and $90.0M). TuHURA Biosciences, Inc. has the higher net margin (0.00% vs −253.4%) and the lower return on invested capital (−74.2% vs 0.00%). Across the 15 metrics below, TuHURA Biosciences, Inc. leads on 8 and Coherus Oncology, Inc. on 7.
Valuation
Profitability
| Metric | CHRS | HURA | Biotechnology median |
|---|---|---|---|
| Gross margin | 69.81% | 0.00% | 68.81% |
| Operating margin | (275.94%) | 0.00% | 0.00% |
| Net margin | (253.43%) | 0.00% | 0.00% |
| Free cash flow margin | (323.85%) | 0.00% | 0.00% |
| Return on equity | (240.54%) | (163.84%) | (50.30%) |
| Return on assets | (39.54%) | (92.31%) | (45.47%) |
| Return on invested capital | 0.00% | (74.20%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack